Perjeta

Pharma

BMS' Opdivo hits more approvable goal in early NSCLC

Opdivo's latest event-free survival win in neoadjuvant NSCLC adds to the drug's previous pathologic complete response success in the same trial.
Angus Liu Nov 8, 2021 10:35am

AZ, Daiichi start Enhertu head-to-head trial in 1L breast cancer

Jun 14, 2021 10:35am

Roche pharma drops on biosimilar attack—again

Apr 21, 2021 11:25am

Roche CFO names innovation as Roche's defense against biosims

Jan 11, 2021 12:58pm

Roche wards off Herceptin copycats with Perjeta combo product

Jun 30, 2020 11:44am

SABCS: Roche's Perjeta builds case as HER2-positive add-on

Dec 11, 2019 8:00am